Novel Mutation Found to Affect Metabolism of Tegafur

06/13/2002
By Mark Moran

A novel mutation of the cytochrome P 2A6 (CYP2A6) gene found in one patient during clinical trials of a new anti-cancer drug containing tegafur appears to account for poor metabolism of the agent.

 Japanese researchers tested a drug containing tegafur and 5-chloro-2,4-dihydroxypyridine, an inhibitor of dihydropyrimidine dehydrogenase, in five gastric cancer patients. In one patient, the total area under the plasma tegafur concentration-time curve was four times what it was in the other four patients.

Alleles from the patient for the CYP2A6 genes–which are reported to metabolize tegafur to yield 5-fluorouracil–were completely sequenced. It was found that one allele was CYP2A6*4C, which was a whole deleted allele for the human CYP2A6 gene.

 The other allele was a novel mutant allele (CYP2A6*11) in which thymine at nucleotide 670 was changed to cytosine. The nucleotide change caused an amino acid change from serine at residue 224 to proline.

לכתבה המלאה 

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים

© ‫ e-Med
 כל הזכויות שמורות

 

התכנים המוצגים באתר זה מיועדים לאנשי צוות רפואי בלבד

אם כבר נרשמת, יש להקליד את פרטי הזיהוי שלך
עדיין לא נרשמת? באפשרותך לבצע רישום כאן
להרשמה לאתר